Followers | 145 |
Posts | 27567 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Sunday, November 10, 2013 11:49:19 AM
Assuming that Check Point pays a tax rate of 5-6%, its tax liability will be $82-102 million (NIS 300-360 million).
10 November 13 17:31, Tali Tsipori
Check Point Software Technologies Ltd. (Nasdaq: CHKP), Israel Chemicals Ltd. (TASE: ICL), and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) are members of an exclusive club of corporations that obtained huge tax breaks and were exempt from the companies tax under the Law for the Encouragement of Capital Investment. Now with the pending deadline of the directive granting a discount on taxes on dividends paid from trapped profits, the companies are "compelled" to open their wallets and pay some taxes. Nonetheless, the tax that some companies have agreed, or will agree, to pay is a fraction of the full amount they would have paid were it not for the directive.
We will begin with the biggest of the three companies, Teva. The Israeli generic giant, which is going through a serious management crisis and has a market cap of $32.5 billion, stated in its financial report for the third quarter that it has $15.14 billion (NIS 53.5 billion) in trapped profits, and if it were to pay tax on the distribution of a dividend from them, the tax would total $2.13 billion (NIS 7.5 billion).
This is only theoretical. The trapped profits law is the result of the Law for the Encouragement of Capital Investment, which was enacted in 1959, to encourage investment in Israel. The law states that any company defined as an "approved enterprise" is eligible for tax breaks; in effect paying a negligible tax rate. It also states that a company subject to the law that wants to distribute dividend from the untaxed profits will pay a dividend tax of 15% on top of the companies tax rate of 25%, for a total tax rate of 40%.
This condition resulted in corporations, which accumulated huge profits over the decades, not distributing dividends because of the tax liability that would have applied. To avoid paying the tax, they essentially trapped the untaxed profits. The result was the trapped profits law, which basically allows the corporations to pay a much lower tax rate than the 15% rate on dividends distributed from the untaxed profits, and releases them from paying the 25% companies tax.
In effect, the law grants the companies an additional tax break. The law sets out different tax plans, and there is no uniform tax rate for all companies, so it is possible that some companies will pay far less than the 15%.
As for Teva, it stated in its latest financial report that if it utilizes the trapped profits law, it would pay a maximum one-time tax assessment of $700 million (NIS 2.5 billion), or a tax rate of just 4.6%. In May, the company said that it would pay NIS 336 million in taxes on NIS 5.5 billion in trapped profits (a tenth of its total trapped profits), a tax rate of just 6.1%.
On the basis of Teva's statement that its tax assessment will be $700 million, and excluding what it paid in May, the question is: Will Teva pay NIS 2.1 billion in taxes to the Israel Tax Authority?
As for Check Point, which has a market cap of $11.6 billion, it stated in its financial report for the third quarter that it has $1.7 billion in trapped profits. Check Point, in contrast to Teva, did not mention the amount of its tax assessment, so at this point it is only possible to use Teva's tax assessment as a baseline for an estimate. Assuming that Check Point pays a tax rate of 5-6%, its tax liability will be $82-102 million (NIS 300-360 million).
Published by Globes [online], Israel business news - www.globes-online.com - on November 10, 2013
Recent TEVA News
- Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News • IH Market News • 05/09/2024 11:53:19 AM
- Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook • Business Wire • 05/08/2024 11:00:00 AM
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia • Business Wire • 05/08/2024 10:30:00 AM
- Teva to Present at the 2024 Bank of America Healthcare Conference • Business Wire • 05/02/2024 10:30:00 PM
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets • Business Wire • 05/02/2024 12:30:00 PM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/30/2024 08:00:00 AM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • Business Wire • 04/16/2024 09:43:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 04/16/2024 09:30:00 PM
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets • Business Wire • 04/16/2024 12:00:00 PM
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China • Business Wire • 04/11/2024 12:30:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 • Business Wire • 04/09/2024 08:30:00 PM
- New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 • Business Wire • 04/06/2024 05:00:00 PM
- Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate • Business Wire • 04/04/2024 12:30:00 PM
- Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement • Business Wire • 04/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:27:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:46:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:43:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:39:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:35:36 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM